National Bank of Canada
ACAD icon

National Bank of Canada’s Acadia Pharmaceuticals ACAD Stock Holding History

National Bank of Canada’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-134
Closed -$2.89K – 2828
2025
Q2 		$2.89K Buy
134
+117
+688% +$2.17K ﹤0.01% 2575
2025
Q1 		$276 Sell
17
-867
-98% -$15.8K ﹤0.01% 2676
2024
Q4 		$16.2K Sell
884
-100
-10% -$1.61K ﹤0.01% 2225
2024
Q3 		$15.1K Sell
984
-1
-0.1% -$17 ﹤0.01% 1996
2024
Q2 		$15.8K Hold
985
– – ﹤0.01% 2024
2024
Q1 		$15K Buy
985
+550
+126% +$13.6K ﹤0.01% 2090
2023
Q4 		$13.4K Buy
435
+105
+32% +$2.51K ﹤0.01% 2106
2023
Q3 		$7.08K Hold
330
– – ﹤0.01% 2282
2023
Q2 		$7.9K Hold
330
– – ﹤0.01% 2242
2023
Q1 		$6.21K Hold
330
– – ﹤0.01% 2250
2022
Q4 		$5.25K Hold
330
– – ﹤0.01% 2320
2022
Q3 		$5K Buy
330
+35
+12% +$567 ﹤0.01% 2320
2022
Q2 		$4K Hold
295
– – ﹤0.01% 2447
2022
Q1 		$7K Buy
+295
New +$7.14K ﹤0.01% 2457

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

National Bank of Canada's ACAD Position: Q3 2025 in Review

National Bank of Canada sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 134 shares — an estimated $2.89K sold.

National Bank of Canada first reported a position in ACAD in Q1 2022 and held it in 14 quarters. The position peaked at $16.2K in Q4 2024. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • National Bank of Canada reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 134 Acadia Pharmaceuticals shares in Q3 2025, an estimated $2.89K.
  • National Bank of Canada first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 14 quarters.
  • National Bank of Canada's Acadia Pharmaceuticals position peaked at $16.2K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.